Nalaganje...
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
BACKGROUND: Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker for various cancers. We investigated...
Shranjeno v:
| izdano v: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6444867/ https://ncbi.nlm.nih.gov/pubmed/30935424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5483-x |
| Oznake: |
Označite
Brez oznak, prvi označite!
|